Triple blood pressure pill reached near-full effect in two weeks
In two randomized trials involving 3,299 adults with hypertension, a three-drug pill achieved virtually all its blood pressure reduction within two weeks.
Double-blind, placebo-controlled
Limit: Blood pressure changes during the active run-in also reflected regression to the mean
Edited by Boris Djordjevic · AgingResearch.News
In 3,299 adults with hypertension, researchers analyzed home blood pressure readings from two double-blind randomized trials. The pill combined three blood pressure medicines: telmisartan, amlodipine and indapamide. One trial compared daily doses of 10/1.25/0.625 or 20/2.5/1.25 milligrams, respectively, with placebo for four weeks. With either dose, systolic pressure—the upper blood pressure number—reached its maximum reduction within one week, with no apparent further reduction.
In the other trial, existing blood pressure medicines were switched to the triple pill at 20/2.5/1.25 milligrams daily for four weeks before randomization. Participants then continued it or switched to two of its drugs at unchanged doses for six weeks. Switching typically led to increased systolic pressure within two weeks, although this took somewhat longer when amlodipine was withdrawn. All doses then doubled for another six weeks; additional reductions reached their maximum within two weeks.
Why it matters
For adults with hypertension, the authors said these timing estimates could guide choices between two- and three-drug therapy and help schedule follow-up visits.
Caveats
This analysis estimated the timing of blood pressure changes from home readings, not long-term health benefits. It covered adults with hypertension; the congress abstract does not report adverse events or the size of the pressure reductions.
The paper
George Institute for Global Health; The George Institute for Global Health
ESC Congress 2026 Abstract, Oct 26, 2026, Open access
Presented at ESC Congress 2026
